However, a disaffinity was revealed in that when treating ovarian cancer cell lines with a PI3K inhibitor, LY294002, a reduction in gonadotropin-induced MMP-2 activity but with little change in MMP-9 activity was noted [63]. This evidence concerns the gene MMP2 and ovarian carcinoma.